悦心健康
(002162)
| 流通市值：39.13亿 | | | 总市值：39.18亿 |
| 流通股本：9.18亿 | | | 总股本：9.20亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 195,759,896 | 1,204,147,736.16 | 888,897,808.68 | 558,526,815.52 |
| 营业收入 | 195,759,896 | 1,204,147,736.16 | 888,897,808.68 | 558,526,815.52 |
| 利息收入 | 0 | - | - | - |
| 已赚保费 | 0 | - | - | - |
| 手续费及佣金收入 | 0 | - | - | - |
| 二、营业总成本 | 204,254,012.13 | 1,229,212,295.42 | 912,768,563.09 | 558,570,295.57 |
| 营业成本 | 149,172,516.12 | 947,366,396.74 | 700,788,490.68 | 429,182,310.51 |
| 利息支出 | 0 | - | - | - |
| 手续费及佣金支出 | 0 | - | - | - |
| 退保金 | 0 | - | - | - |
| 赔付支出净额 | 0 | - | - | - |
| 提取保险合同准备金净额 | 0 | - | - | - |
| 保单红利支出 | 0 | - | - | - |
| 分保费用 | 0 | - | - | - |
| 税金及附加 | 2,386,188.13 | 12,903,690.24 | 9,571,249.75 | 5,438,431.57 |
| 销售费用 | 34,746,733.79 | 166,821,722.84 | 125,399,345.99 | 79,888,353.66 |
| 管理费用 | 12,584,998.11 | 74,423,461.89 | 56,358,628.21 | 30,521,483.67 |
| 研发费用 | 1,065,664.86 | 7,918,208.12 | 5,860,659.43 | 3,694,163.6 |
| 财务费用 | 4,297,911.12 | 19,778,815.59 | 14,790,189.03 | 9,845,552.56 |
| 其中:利息费用 | 5,472,390.14 | 23,901,704.73 | 18,199,003.17 | 12,081,760.21 |
| 其中:利息收入 | 1,280,984.92 | 5,071,479.92 | 4,250,415.68 | 2,760,481.98 |
| 加:公允价值变动收益 | 130,000 | 3,039,938.77 | 1,488,200 | 1,488,200 |
| 加:投资收益 | 22,427.47 | -8,881,173.46 | -3,930,780.88 | -4,743,621.26 |
| 汇兑收益 | 0 | - | - | - |
| 资产处置收益 | 12,472.11 | - | - | - |
| 资产减值损失(新) | 0 | -46,949,276.21 | -5,027,045.17 | -5,027,045.17 |
| 信用减值损失(新) | 0 | -38,710,114.03 | -4,176,271.2 | 11,462,036.6 |
| 其他收益 | 204,719.59 | 6,430,583.58 | 4,515,745.21 | 3,902,882.04 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -8,124,496.96 | -110,134,600.61 | -31,000,906.45 | 7,038,972.16 |
| 加:营业外收入 | 241,700 | 1,517,668.82 | 1,048,556.47 | 876,575.11 |
| 减:营业外支出 | -7,096.09 | 2,803,957.19 | 371,409.83 | 91,291.55 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -7,875,700.87 | -111,420,888.98 | -30,323,759.81 | 7,824,255.72 |
| 减:所得税费用 | 798,782.02 | 38,604,086.4 | 5,437,824.01 | 6,680,468.11 |
| 六、净利润 | -8,674,482.89 | -150,024,975.38 | -35,761,583.82 | 1,143,787.61 |
| 持续经营净利润 | -8,674,482.89 | -150,024,975.38 | -33,359,977.16 | 2,824,712.32 |
| 终止经营净利润 | 0 | - | -2,401,606.66 | -1,680,924.71 |
| 归属于母公司股东的净利润 | -8,328,206.11 | -147,124,591.55 | -33,072,851.16 | 2,428,896.87 |
| 少数股东损益 | -346,276.78 | -2,900,383.83 | -2,688,732.66 | -1,285,109.26 |
| (一)基本每股收益 | -0.01 | -0.16 | -0.04 | 0 |
| (二)稀释每股收益 | -0.01 | -0.16 | -0.04 | 0 |
| 八、其他综合收益 | 0 | -9,518.45 | -26,355.54 | -6,350.16 |
| 归属于母公司股东的其他综合收益 | 0 | -5,711.07 | -15,813.33 | -3,810.1 |
| 九、综合收益总额 | -8,674,482.89 | -150,034,493.83 | -35,787,939.36 | 1,137,437.45 |
| 归属于母公司股东的综合收益总额 | -8,328,206.11 | -147,130,302.62 | -33,088,664.49 | 2,425,086.77 |
| 归属于少数股东的综合收益总额 | -346,276.78 | -2,904,191.21 | -2,699,274.87 | -1,287,649.32 |
| 公告日期 | 2025-04-26 | 2025-02-28 | 2024-10-26 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |